• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

CRH Medical Securityholders Approve Acquisition By WELL Health

Share:

April 20, 2021

CRH Medical Corporation (TSX: CRH) (NYSE: CRHM) (“CRH” or the “Company”) today announced that its security holders approved the acquisition of CRH by a subsidiary of WELL Health Technologies Corp. (“WELL Health”) at the special meeting of CRH security holders today.

The special resolution approving the Arrangement was approved by (i) 97.30% of the votes cast by CRH shareholders present in person or represented by proxy at the meeting; (ii) 97.49% of the votes cast by CRH shareholders, share unitholders, and option holders voting as a single class present in person or represented by proxy at the meeting; and (iii) 97.27% of the votes cast by “minority” CRH shareholders in accordance with Part 8 of Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions.

Upon closing of the arrangement, CRH shareholders will receive US$4.00 per common share in cash, less any applicable withholding taxes.

The arrangement is subject to court and regulatory approvals and clearances, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed on or about April 22, 2021.

Cautionary Note Regarding Forward-Looking Statements

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Certain statements and information included or incorporated by reference in this document may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements include statements regarding the acquisition of the Company by WELL Health and the expected timetable for completing such proposed transaction, as well as all other statements that are not statements of historical fact. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “plan,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements reflect current expectations of management regarding future events and performance as of the date of this document and involve known and unknown risks, uncertainties, and other factors which may cause our actual results to be materially different from those expressed or implied by any forward-looking statements. These forward-looking statements should not be read as guarantees of future results, and there can be no assurance that the results expressed or implied by any forward-looking statements will be achieved. Important factors that could cause actual results to differ materially from the results discussed in forward-looking statements include: (i) the risk that regulatory or other approvals required for the transaction may be delayed or not obtained, or are obtained subject to conditions that are not anticipated; (ii) the possibility that certain other conditions to the consummation of the proposed transaction will not be satisfied or completed on a timely basis, or at all; (iii) the risk that the financing necessary for the consummation of the proposed transaction is unavailable at the closing; (iv) the risk of disruption from the announcement, pendency and/or completion of the potential transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; (v) uncertainties related to developments in the COVID-19 pandemic and its impact on the Company’s operations and the completion of the proposed transaction; and (vi) uncertainties related to general economic, financial, regulatory and political conditions, as well as potential changes in law and regulatory interpretations.

Additional factors that could cause actual results to differ materially from expectations include, without limitation, the risks identified by the Company in its most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K, which are available on EDGAR at www.sec.gov/edgar.shtml or on the Company’s website at www.crhmedcorp.com. The Company disclaims any intent or obligations to update or revise publicly any forward-looking statements whether as a result of new information, estimates or options, future events or results or otherwise, unless required to do so by law.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Mazor Robotics Shareholders Approve Merger Agreement With MedtronicMazor Robotics Shareholders Approve Merger Agreement With Medtronic
  • National Imaging Solutions Acquires DynaRadNational Imaging Solutions Acquires DynaRad
  • Humana to Purchase Enclara Healthcare, Hospice PBMHumana to Purchase Enclara Healthcare, Hospice PBM
  • Global Retail Clinics in Store Healthcare Market Insights 2020 – By Type and Function, Growth Drivers, Industry Insights, Future Trends and Industry VerticalsGlobal Retail Clinics in Store Healthcare Market Insights 2020 – By Type and Function, Growth Drivers, Industry Insights, Future Trends and Industry Verticals
  • How AI Is Revolutionizing HealthcareHow AI Is Revolutionizing Healthcare
  • Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid LeukemiaTiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia
  • Montagu Private Equity LLP Completes Acquisition of the RTI Surgical OEM BusinessMontagu Private Equity LLP Completes Acquisition of the RTI Surgical OEM Business
  • Novartis bids goodbye to Hudson, hello to new pharma chief TschudinNovartis bids goodbye to Hudson, hello to new pharma chief Tschudin

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications